Quarterly Updates6 Nov 2025, 07:05 pm
Lupin Ltd Reports Strong Q2 FY2026 Results with 24.3% YoY Sales Growth
AI Summary
Pharma major Lupin Limited reported its financial performance for the quarter ending September 30, 2025. The company's sales stood at INR 68,314 Mn, marking a 24.3% YoY growth. The EBITDA was INR 24,313 Mn, up 90.3% YoY, and the PAT was INR 14,848 Mn, up 72.8% YoY. The company's investment in R&D was INR 5,091 Mn (7.5% of sales).
Key Highlights
- Sales stood at INR 68,314 Mn, marking a 24.3% YoY growth.
- EBITDA was INR 24,313 Mn, up 90.3% YoY.
- PAT was INR 14,848 Mn, up 72.8% YoY.
- Investment in R&D was INR 5,091 Mn (7.5% of sales).
- Net Debt stands at INR -16,646 Mn, and Net Debt Equity stands at -0.08.